- Antenatal Testing
- Carrier Testing
- Sweat Tests
- CFTR-Related Metabolic Syndrome (CRMS)
- Newborn Screening
- Prenatal Screening
Cystic fibrosis (CF) diagnostics market size was valued at USD 8.13 billion in 2023, growing at a CAGR of 18% from 2024-30. Cystic fibrosis (CF) is a chronic, genetic disease that causes persistent lung infections and limits the ability to breathe over time. Several mutations in the gene is responsible for Cystic fibrosis that encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein. Patients with CF have inherited two copies of the defective CF gene one copy from each parent. Both parents must have at least one copy of the defective gene. Currently, there are approximately 70,000 people who are suffering from cystic fibrosis worldwide, according to the Cystic Fibrosis Foundation (CFF). Some of the popular methods of diagnosis are antenatal testing, carrier testing, and other tests such as genetic tests and sweat tests According to Cystic Fibrosis Foundation, the incidence of these hereditary disorders is constantly growing. Nonprofit organizations are investing huge amounts of funds to find various therapeutics for CF and to support research & developmental activities.
Cystic Fibrosis (CF) Diagnostics Market Key Developments:
In February 2018, Luminex's xTAG Cystic Fibrosis 71 Kit v2 was approved for sale with LICENSALE.COM in Brazil. In March 2017, Elucigene Diagnostics announced the official launch of a new CF-Italia kit (CF1ITB1). In April 2017, Elucigene Diagnostics partnered with Southern Cross Diagnostics in order to expand in Australia and New Zealand markets.
Cystic Fibrosis Cf Diagnostics Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
18%
Largest Market
North America
Fastest Growing Market
Europe
Cystic Fibrosis (CF) Diagnostics Market Dynamics
The major driver for the market is improved diagnostic technologies. Increase in investment and awareness about genetic diseases are aiding in development of diagnostic technologies, which will fuel the market growth. The high cost of the drugs and treatment may hamper the growth of the market. The global cystic fibrosis diagnostics market is expected to witness tremendous growth. Novel diagnostic tools for cystic fibrosis are being developed. The scientists at Stanford University, have developed a DNA test for the accurate and comprehensive screening of newborns for cystic fibrosis. By this test the next-generation DNA sequencing can be identified and this test is considered to be less expensive and less time-consuming technology.
North-America Got Significant Share
Cystic Fibrosis (CF) Diagnostics Market Regional Analysis
Geographically, global Cystic Fibrosis (CF) Diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The higher incidence rate of cystic fibrosis is observed in North America. The median age of the person with cystic fibrosis is currently 33.4 years according cystic fibrosis foundation national patient registry. Followed by North America is the European region which has more affected population with cystic fibrosis. Out of this affected population, 51.8% were adults and 48.2% were less than 18 years old. Whereas the birth prevalence of CF is higher in United Kingdom, Ireland, Romania, and Bulgaria. When it comes to the Asian region, the prevalence of cystic fibrosis is seen to be very low. The Middle East and Africa holds the lowest share in the market, especially countries in the African region.
Latin America
Europe
Asia Pacific
Middle East
North America
Cystic Fibrosis Cf Diagnostics Market Segmentation
By Test Type
By Product Type
- Diagnostic Kits
- Reagents
- Others
By End User
- Hospital
- Diagnostic centers
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa.
Frequently Asked Questions
The cystic fibrosis (CF) diagnostics market size was valued at USD 8.13 billion in 2023, growing at a CAGR of 18% from 2024-30.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
The cystic fibrosis (CF) diagnostics market key players are: Elucigene, Asper Biogene, ELITechGroup, Natera, Inc., Randox Laboratories Ltd., Luminex Corporation, Appolon Bioteck, Arazy Group, Illumina Inc.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019 to 2023) and forecast (2024 to 2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
| 1.Executive Summary |
| 2.Global Cystic Fibrosis Cf Diagnostics Market Introduction |
| 2.1.Global Cystic Fibrosis Cf Diagnostics Market - Taxonomy |
| 2.2.Global Cystic Fibrosis Cf Diagnostics Market - Definitions |
| 2.2.1.Test Type |
| 2.2.2.Product Type |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Cystic Fibrosis Cf Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cystic Fibrosis Cf Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cystic Fibrosis Cf Diagnostics Market By Test Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Antenatal Testing |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Carrier Testing |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sweat Tests |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. CFTR-Related Metabolic Syndrome (CRMS) |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Newborn Screening |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Prenatal Screening |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6.Global Cystic Fibrosis Cf Diagnostics Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Diagnostic Kits |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Reagents |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Cystic Fibrosis Cf Diagnostics Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Diagnostic centers |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Cystic Fibrosis Cf Diagnostics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Antenatal Testing |
| 9.1.2.Carrier Testing |
| 9.1.3.Sweat Tests |
| 9.1.4.CFTR-Related Metabolic Syndrome (CRMS) |
| 9.1.5.Newborn Screening |
| 9.1.6.Prenatal Screening |
| 9.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Diagnostic Kits |
| 9.2.2.Reagents |
| 9.2.3.Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital |
| 9.3.2.Diagnostic centers |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Test Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antenatal Testing |
| 10.1.2.Carrier Testing |
| 10.1.3.Sweat Tests |
| 10.1.4.CFTR-Related Metabolic Syndrome (CRMS) |
| 10.1.5.Newborn Screening |
| 10.1.6.Prenatal Screening |
| 10.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Diagnostic Kits |
| 10.2.2.Reagents |
| 10.2.3.Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital |
| 10.3.2.Diagnostic centers |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Test Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antenatal Testing |
| 11.1.2.Carrier Testing |
| 11.1.3.Sweat Tests |
| 11.1.4.CFTR-Related Metabolic Syndrome (CRMS) |
| 11.1.5.Newborn Screening |
| 11.1.6.Prenatal Screening |
| 11.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Diagnostic Kits |
| 11.2.2.Reagents |
| 11.2.3.Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital |
| 11.3.2.Diagnostic centers |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Test Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antenatal Testing |
| 12.1.2.Carrier Testing |
| 12.1.3.Sweat Tests |
| 12.1.4.CFTR-Related Metabolic Syndrome (CRMS) |
| 12.1.5.Newborn Screening |
| 12.1.6.Prenatal Screening |
| 12.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Diagnostic Kits |
| 12.2.2.Reagents |
| 12.2.3.Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital |
| 12.3.2.Diagnostic centers |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Cystic Fibrosis Cf Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Test Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antenatal Testing |
| 13.1.2.Carrier Testing |
| 13.1.3.Sweat Tests |
| 13.1.4.CFTR-Related Metabolic Syndrome (CRMS) |
| 13.1.5.Newborn Screening |
| 13.1.6.Prenatal Screening |
| 13.2. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Diagnostic Kits |
| 13.2.2.Reagents |
| 13.2.3.Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital |
| 13.3.2.Diagnostic centers |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Elucigene |
| 14.2.2.Asper Biogene |
| 14.2.3.ELITechGroup |
| 14.2.4.Natera, Inc. |
| 14.2.5.Randox Laboratories Ltd. |
| 14.2.6.Luminex Corporation |
| 14.2.7.Appolon Bioteck |
| 14.2.8.Arazy Group |
| 14.2.9.Illumina Inc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Elucigene
- Asper Biogene
- ELITechGroup
- Natera, Inc.
- Randox Laboratories Ltd.
- Luminex Corporation
- Appolon Bioteck
- Arazy Group
- Illumina Inc.